Shareholders ofCepheid(NASDAQ: CPHD), a molecular diagnostics company,are having a pleasant start to the short trading week. News broke this morning that the company has agreed to be acquired by ...
Collaboration to leverage Oxford Nanopore's sequencing platform and Cepheid's GeneXpert system to advance the field of sequencing for infectious diseases OXFORD, United Kingdom and SUNNYVALE, Calif., ...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...
SUNNYVALE, Calif., Feb. 10, 2016 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced that Warren Kocmond, formerly Executive Vice President and Chief Operating Officer, has been promoted to the ...
Cepheid (NAS: CPHD) carries $39.8 million of goodwill and other intangibles on its balance sheet. Sometimes goodwill, especially when it's excessive, can foreshadow problems down the road. Could this ...
Cepheid's performance in the first quarter was driven by robust growth in clinical product sales resulting from test utilization in the emerging HAI test market for Xpert MRSA, continued adoption of ...
Share price of CepheidCPHD shot up significantly following Danaher Corp's DHR historical announcement to take over this prominent molecular diagnostics player at a total enterprise value of $4 billion ...
SUNNYVALE, Calif. (AP) -- Molecular diagnostics company Cepheid said Thursday it took a loss in the third quarter on costs related to a patent lawsuit. In late September Cepheid agreed to settle a ...
Danaher Corporation announced that it has entered into a definitive merger agreement with Cepheid pursuant to which Danaher will acquire all of the outstanding shares of Cepheid for $53.00 per share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback